Thymoquinone Derived From Black Seed: Cytotoxicity and Inhibitory Effect Against MRSA and MSSA Infections

ABSTRACT

Staphylococcus aureus (S. aureus) is known for its ability to colonize human body, with approximately 30% of individuals harbouring it asymptomatically. While it can cause benign skin infections, S. aureus can lead to severe diseases such as hospital-acquired pneumonia (HAP) and bacteremia, especially when methicillin-resistant strains (MRSA) are involved. MRSA has become a major challenge in healthcare setting due to its virulence and extensive antibiotic resistance, complicating treatment options and increasing patient morbidity and mortality. The mecA gene, which encodes for PBP2a, contributes to this resistance, leading to poor efficacy of most beta-lactam antibiotics. This phenomenon has created an urgent need for alternative therapies to combat resistant strains. Drug repositioning has emerged as a promising strategy, utilizing existing compounds for novel therapeutic applications. Thymoquinone (TQ), a bioactive compound derived from Nigella sativa (black seed), displays antimicrobial properties against various pathogens, potentially including MRSA. This study aims for the first time to investigate the differential effects of TQ on MRSA and methicillin-sensitive S. aureus (MSSA), focusing on its antibacterial activity, resistance profiles, and toxicity. A total of 40 isolates (20 MRSA and 20 MSSA) were analyzed using standardized methods. Preliminary results indicate a statistically significant (p value 0.0002) difference in MIC values between MRSA and MSSA, with MRSA exhibiting higher resistance. The cytotoxicity of TQ, evaluated with human breast cancer cells, demonstrates a direct correlation with TQ concentration. Overall, the findings of this study provided insights into TQ's therapeutic potential, establishing a foundation for developing effective strategies against MRSA and contributing to the ongoing fight against antibiotic resistance.

Keywords: Thymoquinone, AMR, MRSA, MSSA, Hospital-acquired pneumonia

Bahrain Med Bull 2025; 47 (3): 2272-2278

*	Department of Clinical Physiology Faculty of Medicine,
	King Abdulaziz University, Jeddah, Saudi Arabia.
**	Master's Students, Department of Clinical Physiology Faculty of Medicine,
	King Abdulaziz University, Jeddah, Saudi Arabia.
***	Department of Clinical Microbiology Laboratory,
	King Abdulaziz University Hospital, Jeddah 21589,
	Saudi Arabia. E-mail: kaibrahem@kau.edu.sa
****	Department of Clinical Microbiology and Immunology,
	Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
****	Department of Clinical Biochemistry, Faculty of Medicine,
	King Abdulaziz University Jeddah, 21589, Saudi Arabia.
*****	Department of Clinical Nutrition, Faculty of Applied Medical Sciences,
	King Abdulaziz University, Jeddah, Saudi Arabia.
*****	Department of Medical Laboratory Sciences,
	Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
*****	Department of Microbiology and Parasitology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
*****	Department of Medical Education, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
*****	Department of Medicine, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
*****	Vaccines and Immunotherapy Unit, King Fahd Medical Research Center,
	King Abdulaziz University, Jeddah 21589, Saudi Arabia.
*****	Regenerative Medicine Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
*****	Food, Nutrition and Lifestyle Unit, King Fahd Medical Research Centre,
	King Abdulaziz University, Jeddah 21551, Saudi Arabia.
*****	Special Infectious Agents Unit BSL-3, King Fahd Medical Research Center,
	King Abdulaziz University, Jeddah, Saudi Arabia.